$1.16 Billion is the total value of Sarissa Capital Management LP's 11 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 10.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALKS | Buy | ALKERMES PLC | $326,570,000 | -19.9% | 14,040,000 | +6.3% | 28.27% | -11.6% |
| GILD | Sell | GILEAD SCIENCES INC | $209,792,000 | +1.2% | 2,889,300 | -2.6% | 18.16% | +11.6% |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $191,107,000 | -10.7% | 16,390,000 | 0.0% | 16.54% | -1.5% | |
| BIIB | BIOGEN INC | $154,269,000 | -15.2% | 643,000 | 0.0% | 13.35% | -6.5% | |
| INVA | INNOVIVA INC | $114,092,000 | +3.2% | 6,614,000 | 0.0% | 9.88% | +13.8% | |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $64,873,000 | +49.6% | 19,250,000 | +126.5% | 5.62% | +65.0% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $55,948,000 | -0.8% | 4,039,600 | +2.9% | 4.84% | +9.3% |
| MRSN | MERSANA THERAPEUTICS INC | $26,742,000 | -34.0% | 4,299,297 | 0.0% | 2.32% | -27.2% | |
| VOR | VOR BIOPHARMA INC | $8,215,000 | -25.9% | 707,010 | 0.0% | 0.71% | -18.3% | |
| New | PEAR THERAPEUTICS INC | $3,102,000 | – | 500,356 | +100.0% | 0.27% | – | |
| RGLS | REGULUS THERAPEUTICS INC | $583,000 | -54.4% | 1,851,851 | 0.0% | 0.05% | -50.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.